Key Insights

Highlights

Treatment Research

3 treatments under study, led by Bevacizumab Avastin Genentech Inc

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1/2 (1)

Trial Status

Unknown1
Withdrawn1

Clinical Trials (2)

Showing 2 of 2 trials
NCT01256580Not ApplicableWithdrawn

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

NCT00955630Phase 1/2UnknownPrimary

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Showing all 2 trials

Research Network

Common Treatments

  • Bevacizumab Avastin Genentech Inc1
  • Bevacizumab Dexamethasone Verteporfin Photodynamic Therapy1
  • Ranibizumab1

Active Sponsors

  • Genentech, Inc.1
  • Massachusetts Eye and Ear Infirmary1
  • Retina Associates of Kentucky1

Top Investigators

Related Conditions

  • Myopia1
  • Choroidal Neovascularization1
  • Central Serous Chorioretinopathy Csc1
  • Angioid Streaks1
  • Multifocal Choroiditis1

Activity Timeline